PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of apmJournal's HomeManuscript SubmissionAims and ScopeAuthor GuidelinesEditorial BoardHome
 
Adv Prev Med. 2012; 2012: 149737.
Published online Mar 26, 2012. doi:  10.1155/2012/149737
PMCID: PMC3318197
The Need for Continued Development of Ricin Countermeasures
Ronald B. Reisler 1 * and Leonard A. Smith 2
1Division of Clinical Medicine, Clinical Research Management Inc., Team Ke'aki Tech, United States Army Medical Research Institute of Infectious Diseases, 1425 Porter Street, Fort Detrick, MD 21702-5011, USA
2Division of Toxinology, United States Army Medical Research Institute of Infectious Diseases, 1425 Porter Street, Fort Detrick, MD 21702-5011, USA
*Ronald B. Reisler: ronald.reisler/at/hhs.gov
Academic Editor: Phillip R. Pittman
Received August 1, 2011; Accepted January 10, 2012.
Abstract
Ricin toxin, an extremely potent and heat-stable toxin produced from the bean of the ubiquitous Ricinus communis (castor bean plant), has been categorized by the US Centers for Disease Control and Prevention (CDC) as a category B biothreat agent that is moderately easy to disseminate. Ricin has the potential to be used as an agent of biological warfare and bioterrorism. Therefore, there is a critical need for continued development of ricin countermeasures. A safe and effective prophylactic vaccine against ricin that was FDA approved for “at risk” individuals would be an important first step in assuring the availability of medical countermeasures against ricin.
Articles from Advances in Preventive Medicine are provided here courtesy of
Hindawi Publishing Corporation